Mdxhealth S.A.
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 3 name spellings.
7
Ending by 2030
Sep 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 9 to 25, 2026 · next Dec 9
- 1 fee due Mar 26, 2027The maintenance fee for Method for Predicting and Treating Clinically Significant Prostate Cancer (US 11,767,563) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
- 1 fee due Oct 26, 2027The maintenance fee for Methods for Determining Methylation of the TWIST1 Gene for Bladder Cancer Detection (US 9,322,065) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,113,202 | Method for Determining the Methylation Status of the Promoter Region of the TWIST1 Gene in Genomic DNA from Bladder Cells In force · High confidence | In force | High confidence | |
| US 10,053,724 | Methylation Detection of the MGMT Promoter In force · High confidence | In force | High confidence | |
| US 9,371,569 | Detection and Prognosis of Cervical Cancer In force · Medium confidence | In force | Medium confidence | |
| US 10,041,128 | Methylation of the EPB41L3 Gene or the Promoter of the EPB41L3 Gene in a Test Sample Comprising Cervical Cells In force · Medium confidence | In force | Medium confidence | |
| US 9,322,065 | Methods for Determining Methylation of the TWIST1 Gene for Bladder Cancer Detection In force · High confidence | In force | High confidence | |
| US 9,388,471 | Methylation of the GATA4 Gene in Urine Samples as a Marker for Bladder Cancer Detection In force · High confidence | In force | High confidence | |
| US 9,050,280 | Methylation Detection of MGMT In force · High confidence | In force | High confidence | |
| US 10,260,104 | Method for Using Gene Expression to Determine Prognosis of Prostate Cancer In force · High confidence | In force | High confidence | |
| US 9,605,312 | Methods of Detecting Mutations in Braf and Epigenetic Changes In force · High confidence | In force | High confidence | |
| US 8,725,426 | Gene Expression Profile Algorithm and Test for Determining Prognosis of Prostate Cancer In force · High confidence | In force | High confidence |
Also on record, not counted in the 14: 7 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 7 abandoned · 1 no status recorded